A Hidden Danger in Plain Sight
Maria has type 2 diabetes and a fatty liver. She takes her medication, watches her diet, and gets her cholesterol checked. Her doctor says her numbers look okay. Yet she still worries about her heart. She knows people with diabetes are at higher risk for heart problems, but her standard tests don’t seem to tell the full story.
This is a common and frustrating gap in care. Many people with diabetes and fatty liver disease still develop heart disease, even when their basic cholesterol numbers look fine.
Metabolic dysfunction-associated steatotic liver disease (MASLD), often called fatty liver disease, is very common in people with type 2 diabetes. When these two conditions overlap, the risk for coronary heart disease (CHD) rises sharply.
Coronary heart disease happens when the arteries that supply blood to the heart become narrowed or blocked. It can lead to chest pain, heart attacks, and other serious problems.
Standard cholesterol tests measure total cholesterol, LDL (“bad” cholesterol), HDL (“good” cholesterol), and triglycerides. But these numbers don’t always capture the full picture of heart risk, especially for people with diabetes and fatty liver.
Doctors call this the “residual risk.” Even when standard cholesterol numbers look okay, some people still face a high risk of heart problems. This can leave patients and doctors feeling uncertain about the best next steps.
The Old Way vs. The New Way
For years, doctors have relied on standard lipid profiles to estimate heart risk. These tests are useful, but they have limits. They may not fully capture the risk from other types of fats in the blood.
But here’s the twist: new research suggests that looking at a broader set of blood fat markers—called non-traditional lipid indices—can reveal hidden risks that standard tests miss.
This study doesn’t replace standard cholesterol tests. Instead, it adds more detail to the picture, helping doctors spot risks that might otherwise go unnoticed.
How It Works: A New Set of Tools
Think of your blood fats like a traffic system. Standard cholesterol tests look at the main highway lanes. But there are also side roads, detours, and hidden shortcuts that can cause problems.
Non-traditional lipid indices look at these side roads. They measure things like:
- Remnant cholesterol (RC): Leftover fats that can build up in arteries.
- Atherogenic index of plasma (AIP): A measure of how likely fats are to cause artery plaque.
- Lipoprotein combined index (LCI): A broader look at different fat particles.
- Castelli risk index-II (CRI-II): A ratio that compares different cholesterol types.
The study also used machine learning—a type of computer analysis—to find patterns in these numbers. Machine learning can spot complex connections that might be hard to see with simple statistics.
To keep things clear, the researchers used special tools (called SHAP and LIME) that explain why the computer made a certain prediction. This helps doctors and patients trust the results.
Researchers looked at 1,823 patients with both MASLD and type 2 diabetes. They came from multiple medical centers. After matching patients with similar characteristics, they analyzed data from 630 people for risk associations and 1,665 people to build the machine learning model. A separate group of 158 patients was used to test the model.
The study was retrospective, meaning it looked at past data rather than testing new treatments.
All eight non-traditional lipid indices were linked to a higher risk of coronary heart disease. But one stood out: the Castelli risk index-II (CRI-II).
Patients with higher CRI-II levels had about 2.4 times the odds of having coronary heart disease, even after accounting for other factors. This makes CRI-II a strong, independent marker of risk.
Other indices, like remnant cholesterol and the atherogenic index of plasma, showed a more complex relationship. Their link to heart risk wasn’t a straight line—it went up and down in ways that depended on the person’s overall health profile.
CRI-II also correlated with the severity of artery blockages, as measured by a test called the Gensini score. This means higher CRI-II wasn’t just linked to having heart disease—it was linked to having more serious heart disease.
But There’s a Catch
This is where things get interesting. The study shows these non-traditional indices are promising, but they are not yet ready for routine use in doctor’s offices.
This doesn’t mean this treatment is available yet.
The model is still being refined, and more research is needed to confirm these findings in broader groups of people.
This study adds to a growing body of evidence that standard cholesterol tests don’t tell the whole story, especially for people with diabetes and fatty liver disease. By looking at a wider range of blood fat markers, doctors may be able to better identify who is at risk—and who needs closer monitoring or more aggressive treatment.
Machine learning offers a way to make sense of these complex numbers, but it’s not a replacement for clinical judgment. It’s a tool to help doctors make better decisions.
If you have type 2 diabetes and fatty liver disease, talk to your doctor about your heart risk. Ask whether your current cholesterol tests are giving you the full picture.
These non-traditional lipid indices are not yet standard tests, but they may become part of routine care in the future. For now, they are a research tool.
This study has some important limits. It looked at past data from a specific group of patients, so the results may not apply to everyone. The machine learning model needs more testing in different populations before it can be widely used.
Also, the study doesn’t prove that changing these blood fat numbers will lower heart risk. It only shows an association.
Next steps include testing this approach in larger, more diverse groups of people. Researchers will also need to see if using these non-traditional indices actually improves patient outcomes—like preventing heart attacks or deaths.
If the results hold up, these tests could become part of routine care for people with diabetes and fatty liver disease, helping doctors spot hidden risks and tailor treatment more precisely.